SUBSCRIBE
SUBSCRIBE
News   Policy

FDA Sees Some Drug Delays Amid Safety Focus

May 28, 2008 | 
1 min read

Reuters -- A new focus on drug safety is delaying the approval of some medicines as regulators impose requirements meant to minimize side effects, a top U.S. drug regulator told Reuters on Tuesday.

Regulatory
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Amgen sign at its headquarters in Thousand Oaks, California, USA.
Approvals
Looking Beyond Obesity, Amgen Wins Colorectal Cancer Expansion for Lumakras
January 17, 2025
 · 
2 min read
 · 
Tristan Manalac
Novartis' office building in Marburg, Germany
Patents
Novartis Scrambles to Squelch Copycats as Generics Gain Ground
January 17, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Exterior view of the headquarters of the
Complete response letters
Manufacturing Issues Result in FDA Rejection of Atara’s Cell Therapy
January 16, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
FDA signage at its headquarters in Maryland
Regulatory
After Letter to Commissioner, FDA Finally Gives Vanda Reason for Rejection, Chance for Hearing
January 16, 2025
 · 
2 min read
 · 
Tristan Manalac